Analyst Reco. OptimizeRx Corporation

Equities

OPRX

US68401U2042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
12.89 ^USD	-1.45%		+23.00%	-9.92%

May. 14	Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024
May. 14	OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Initiates Coverage on OptimizeRx With Market Perform Rating, $15 Price Target	Apr. 04	MT
RBC Adjusts OptimizeRx's Price Target to $17 From $14, Keeps Outperform Rating	Jan. 10	MT
Barclays Starts OptimizeRx With Equalweight Rating, $15 Price Target	Jan. 03	MT
Roth MKM Adjusts Price Target on OptimizeRx to $20 From $31, Maintains Buy Rating	23-08-15	MT
Lake street Adjusts OptimizeRx Price Target to $13 From $18, Maintains Buy Rating	23-08-15	MT
Stifel Adjusts Price Target on OptimizeRx to $13 From $16, Maintains Buy Rating	23-08-15	MT
B. Riley Cuts OptimizeRx's Price Target to $18 From $28 on Muted H2 Revenue Expectation, Keeps Buy Rating	23-08-15	MT
RBC Cuts Price Target on OptimizeRx to $14 From $18, Says 'Persisting Macro Headwinds Dampen' 2023 Outlook, Keeps Outperform Rating	23-08-15	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $28 From $30 After 'Slight' Q4 Miss, Keeps Buy Rating	23-03-09	MT
RBC Cuts Price Target on OptimizeRx to $18 From $22 After 'Disappointing' 2023 Guidance; Outperform Rating Kept	23-03-09	MT
B. Riley Resumes OptimizeRx at Buy With $30 PT, Notes Increased Pharma Ad Spend on Digital Channels as Key Market Tailwind	23-02-02	MT
Stifel Starts OptimizeRx at Buy With $19 Price Target	22-11-01	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $37 from $56 After Lower-than-Expected Q2 Results, Keeps Buy Rating	22-08-10	MT
SVB Securities Adjusts OptimizeRx's Price Target to $30 from $38, Keeps Outperform Rating	22-08-10	MT
RBC Cuts Price Target on OptimizeRx to $22 From $50, Maintains Outperform Rating	22-08-10	MT
Piper Sandler Adjusts Price Target on OptimizeRx to $16 From $29, Maintains Neutral Rating	22-08-10	MT
B. Riley Lowers OptimizeRx's Price Target to $56 from $71, Says Consensus Estimates at Risk of Moving Lower into Q2 Print; Keeps Buy Rating	22-07-20	MT
SVB Securities Initiates OptimizeRx at Outperform With $38 Price Target	22-07-15	MT
Piper Sandler Initiates Coverage on OptimizeRx With Neutral Rating, $29 Price Target	22-07-01	MT
RBC Capital Adjusts Price Target on OptimizeRx to $50 From $100, Maintains Outperform Rating	22-05-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. OptimizeRx Corporation

Equities

OPRX

US68401U2042

Analyst Reco.

Filters